TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ITAREPS Trial: A Prospective Randomized Double-blind Controlled Study in IT-aided Mobile Phone-based Relapse Prevention Program in Schizophrenia.
Brief Summary: Information Technology-aided Program of Relapse Prevention in Schizophrenia (ITAREPS) will decrease the number of hospitalizations in patients with schizophrenia or schizoaffective disorder who are treated in the outpatient psychiatric setting, as evidenced by the reduction of the total number of hospitalizations due to relapse of psychosis at the end of the 12-months follow-up period in the active ITAREPS group compared to the control (treatment-as-usual) group.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: antipsychotic dose increase | Arm Label: TAU; Type: PLACEBO_COMPARATOR; Interventions: Other: no intervention | Intervention Type: DRUG; Name: antipsychotic dose increase; Assigned to Arm(s): A | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): TAU
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Telephone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Two way audio/video telemedicine consult | Intervention Type: OTHER; Name: Telephone; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Two way audio/video telemedicine consult; Assigned to Arm(s): 2
C: Arm Label: Remote Arm; Type: EXPERIMENTAL; Interventions: Other: Remote Management | Arm Label: In-office Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: In-Office Care | Intervention Type: OTHER; Name: Remote Management; Assigned to Arm(s): Remote Arm | Intervention Type: OTHER; Name: In-Office Care; Assigned to Arm(s): In-office Arm
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: telemedicine | Intervention Type: OTHER; Name: telemedicine; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ITAREPS Trial: A Prospective Randomized Double-blind Controlled Study in IT-aided Mobile Phone-based Relapse Prevention Program in Schizophrenia.
Brief Summary: Information Technology-aided Program of Relapse Prevention in Schizophrenia (ITAREPS) will decrease the number of hospitalizations in patients with schizophrenia or schizoaffective disorder who are treated in the outpatient psychiatric setting, as evidenced by the reduction of the total number of hospitalizations due to relapse of psychosis at the end of the 12-months follow-up period in the active ITAREPS group compared to the control (treatment-as-usual) group.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Algorithm for phenprocoumon | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: algorithm for phenprocoumon | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: OTHER; Name: Algorithm for phenprocoumon; Assigned to Arm(s): A | Intervention Type: OTHER; Name: algorithm for phenprocoumon; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): C
B: Intervention Type: DRUG; Name: somatropin; Assigned to Arm(s): N/A
C: Arm Label: Standard IWPC warfarin dosing algorithm; Type: ACTIVE_COMPARATOR; Interventions: Genetic: IWPC adapted genotype-guided dosing algorithm for warfarin | Arm Label: Modified IWPC warfarin dosing algorithm; Type: EXPERIMENTAL; Interventions: Genetic: Modified IWPC genetic-guided warfarin dosing algorithm | Arm Label: Historical controls; Type: OTHER; Interventions: Other: Standard of care treatment | Intervention Type: GENETIC; Name: IWPC adapted genotype-guided dosing algorithm for warfarin; Assigned to Arm(s): Standard IWPC warfarin dosing algorithm | Intervention Type: GENETIC; Name: Modified IWPC genetic-guided warfarin dosing algorithm; Assigned to Arm(s): Modified IWPC warfarin dosing algorithm | Intervention Type: OTHER; Name: Standard of care treatment; Assigned to Arm(s): Historical controls
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: antipsychotic dose increase | Arm Label: TAU; Type: PLACEBO_COMPARATOR; Interventions: Other: no intervention | Intervention Type: DRUG; Name: antipsychotic dose increase; Assigned to Arm(s): A | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): TAU

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™)a Fully Human Monoclonal Anti-BLyS Antibody in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 or HGS1006-C1057
Brief Summary: This is a long-term continuation study to provide continuing treatment to subjects with SLE.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
B: Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab | Intervention Type: BIOLOGICAL; Name: Belimumab; Assigned to Arm(s): Belimumab 10 mg/kg
C: Arm Label: Belimumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Belimumab, Drug: Rituximab-placebo, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Belimumab, Drug: Rituximab, Drug: Standard therapy (Excluding Immunosuppressants), Drug: Steroid Taper | Arm Label: Belimumab + Standard therapy; Type: OTHER; Interventions: Drug: Belimumab, Drug: Standard therapy (Including Immunosuppressants), Drug: Steroid Taper | Intervention Type: DRUG; Name: Belimumab; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Belimumab + Rituximab | Intervention Type: DRUG; Name: Rituximab-placebo; Assigned to Arm(s): Belimumab + Placebo | Intervention Type: DRUG; Name: Standard therapy (Including Immunosuppressants); Assigned to Arm(s): Belimumab + Standard therapy | Intervention Type: DRUG; Name: Standard therapy (Excluding Immunosuppressants); Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab | Intervention Type: DRUG; Name: Steroid Taper; Assigned to Arm(s): Belimumab + Placebo, Belimumab + Rituximab, Belimumab + Standard therapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Arm Label: 2.; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Intervention Type: DRUG; Name: belimumab; Assigned to Arm(s): 1, 2.

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blind, Placebo Controlled, Phase IIb Dose Ranging Study (With Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered for 12 Weeks to Rheumatoid Arthritis Patients Receiving Methotrexate.
Brief Summary: This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already available to treat Rheumatoid Arthritis) when added to treatment with methotrexate. The purpose of this study is also to find out which dose of AZD5672 is the most effective at treating RA and to find out how well the body tolerates AZD5672 when taken for up to 12 weeks.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: AZD5672 | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: AZD5672; Assigned to Arm(s): 5
D: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Genetic Counseling for Individuals With Mental Illness: Impact on Knowledge, Risk Perception, Perceived Control and Internalized Stigma.
Brief Summary: People who have experienced mental illnesses like schizophrenia, bipolar disorder or schizoaffective disorder often have a poor understanding of the causes of their illness, and that they are often very worried about how the illness affects their families. In particular, affected individuals worry that there is a high chance that any children that they have will become affected with the same illness. Often, because of this fear, affected individuals choose not to have children.

Genetic counseling is a process where information about the causes of illnesses, and about chances for family members of individuals with these illnesses to become similarly affected is provided in a supportive environment by a specially trained healthcare professional. This study will investigate whether genetic counseling can reduce perceptions of risk and stigma, and increase perceived control and knowledge about the causes of the illness, amongst individuals who have a major mental illness.


Options:
A: Arm Label: 3-9 months PPIUD intervention; Type: EXPERIMENTAL; Interventions: Device: Post-partum IUD | Arm Label: 9-15 months PPIUD intervention; Type: EXPERIMENTAL; Interventions: Device: Post-partum IUD | Intervention Type: DEVICE; Name: Post-partum IUD; Assigned to Arm(s): 3-9 months PPIUD intervention, 9-15 months PPIUD intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
C: Arm Label: GC; Type: EXPERIMENTAL; Interventions: Behavioral: Genetic Counseling | Arm Label: EB; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Booklet | Arm Label: WT; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Genetic Counseling; Assigned to Arm(s): GC | Intervention Type: BEHAVIORAL; Name: Educational Booklet; Assigned to Arm(s): EB
D: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them
Brief Summary: Acute procedural pain in neonates may be alleviated by non-pharmacological procedures. This study objective is to test the efficacy regarding pain attenuation of 3 interventions (skin-to-skin contact versus glucose 25% versus skin to skin associated to glucose 25) versus control in healthy newborn infants submitted to intra-muscular vaccination for Hepatitis B at 48-72 hours of life.


Options:
A: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH
B: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
C: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
D: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them
Brief Summary: Acute procedural pain in neonates may be alleviated by non-pharmacological procedures. This study objective is to test the efficacy regarding pain attenuation of 3 interventions (skin-to-skin contact versus glucose 25% versus skin to skin associated to glucose 25) versus control in healthy newborn infants submitted to intra-muscular vaccination for Hepatitis B at 48-72 hours of life.


Options:
A: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose
B: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Sucrose; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-Pharmacologic Interventions to Relief Pain in Healthy Newborns Submitted to Vaccination to Hepatitis B: a Comparison Between Skin-to-Skin Contact, Glucose 25% and Both of Them
Brief Summary: Acute procedural pain in neonates may be alleviated by non-pharmacological procedures. This study objective is to test the efficacy regarding pain attenuation of 3 interventions (skin-to-skin contact versus glucose 25% versus skin to skin associated to glucose 25) versus control in healthy newborn infants submitted to intra-muscular vaccination for Hepatitis B at 48-72 hours of life.


Options:
A: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A
B: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose
C: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH
D: Arm Label: Co-bedding; Type: EXPERIMENTAL; Interventions: Procedure: Co-bedding (caring for twins in the same incubator) | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Co-bedding (caring for twins in the same incubator); Assigned to Arm(s): Co-bedding

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Transcranial Magnetic Stimulation Efficacy for Major Resistant Depression Compared or Associated With Venlafaxine : a Multicentric Study.
Brief Summary: The purpose of this study is to assess the efficacy of add-on therapy with repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in the treatment of major depressive disorders compared to venlafaxine only (the optimal medication) and to rTMS only.


Options:
A: Arm Label: Sertraline; Type: EXPERIMENTAL; Interventions: Drug: sertraline (Zoloft) | Arm Label: Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: naltrexone (Revia) | Arm Label: Nal/Sert; Type: EXPERIMENTAL; Interventions: Drug: naltrexone (Revia), Drug: sertraline (Zoloft) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: naltrexone (Revia); Assigned to Arm(s): Nal/Sert, Naltrexone | Intervention Type: DRUG; Name: sertraline (Zoloft); Assigned to Arm(s): Nal/Sert, Sertraline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine | Arm Label: C; Type: SHAM_COMPARATOR; Interventions: Other: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine | Intervention Type: OTHER; Name: active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed; Assigned to Arm(s): A | Intervention Type: OTHER; Name: active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine; Assigned to Arm(s): B | Intervention Type: OTHER; Name: sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine; Assigned to Arm(s): C
C: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
D: Arm Label: Escitalopram plus acamprosate; Type: EXPERIMENTAL; Interventions: Drug: acamprosate, Drug: escitalopram, Behavioral: Medical management | Arm Label: Escitalopram plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: escitalopram, Behavioral: Medical management, Drug: Placebo | Intervention Type: DRUG; Name: acamprosate; Assigned to Arm(s): Escitalopram plus acamprosate | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: BEHAVIORAL; Name: Medical management; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Escitalopram plus placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Adolescent Smoking Cessation Programs
Brief Summary: The purpose of this study was to determine if a school-based multi-session group smoking cessation program is more effective than a single session group program.


Options:
A: Arm Label: NOT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: NOT program | Arm Label: NOT controls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: NOT controls | Arm Label: KB intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Kicking Butts intervention | Arm Label: KB controls; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: KB controls | Intervention Type: BEHAVIORAL; Name: NOT program; Assigned to Arm(s): NOT Intervention | Intervention Type: BEHAVIORAL; Name: NOT controls; Assigned to Arm(s): NOT controls | Intervention Type: BEHAVIORAL; Name: Kicking Butts intervention; Assigned to Arm(s): KB intervention | Intervention Type: BEHAVIORAL; Name: KB controls; Assigned to Arm(s): KB controls
B: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CBST | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + CBST; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Pediatric Practice-Based Smoking Intervention; Assigned to Arm(s): N/A

Answer: A